Xueru Yin1, Jiqiao Yang2, Tony Li3, Liyan Song4, Tinglu Han5, Mei Yang1, Huihua Liao1, Jianjun He1, Xiaozhu Zhong1. 1. Department of Infectious Diseases, Zhujiang Hospital of Southern Medical University Guangzhou 510282, People's Republic of China. 2. West China School of Medicine/West China Hospital, Sichuan University Chengdu 610041, People's Republic of China. 3. Yong Loo Lin School of Medicine, National University of Singapore Singapore 119228, The Republic of Singapore. 4. Department of Gynaecology, Puyang Third People's Hospital Puyang 457000, People's Republic of China. 5. Plastic Surgery Hospital, Peking Union Medical College Beijing 100144, People's Republic of China.
Abstract
AIM: There have been many reports on the reduction of liver disease with green tea consumption. This study aims to evaluate the body of evidence related to green tea consumption on the risk of liver disease and determine the effectiveness. METHODS: Electronic searches were conducted in PubMed, CNKI, Wanfang and Weipu databases. Statistical analysis was performed using the software Revman 5.2 and Stata 12.0. RESULTS: Meta-analysis revealed that among green tea drinkers, there was a significant reduction in the risk of liver disease (RR=0.68, 95% CI=0.56-0.82, P=0.000). This trend extends to a broad spectrum of liver conditions including hepatocellular carcinoma (RR=0.74, 95% CI=0.56-0.97, P=0.027), liver steatosis (RR=0.65, 95% CI=0.44-0.98, P=0.039), hepatitis (RR=0.57, 95% CI=0.45-0.73, P=0.000), liver cirrhosis (RR=0.56, 95% CI=0.31-1.01, P=0.053) and chronic liver disease (RR=0.49, 95% CI=0.29-0.82, P=0.007). This trend is also observed regardless of the race of the individual concerned where the Asian, American and European subgroups all demonstrated a reduced risk of liver disease. CONCLUSIONS: Green tea intake reduces the risk of liver disease. However, more long term randomized clinical trials are needed to comprehensively evaluate the health benefits of green tea.
AIM: There have been many reports on the reduction of liver disease with green tea consumption. This study aims to evaluate the body of evidence related to green tea consumption on the risk of liver disease and determine the effectiveness. METHODS: Electronic searches were conducted in PubMed, CNKI, Wanfang and Weipu databases. Statistical analysis was performed using the software Revman 5.2 and Stata 12.0. RESULTS: Meta-analysis revealed that among green tea drinkers, there was a significant reduction in the risk of liver disease (RR=0.68, 95% CI=0.56-0.82, P=0.000). This trend extends to a broad spectrum of liver conditions including hepatocellular carcinoma (RR=0.74, 95% CI=0.56-0.97, P=0.027), liver steatosis (RR=0.65, 95% CI=0.44-0.98, P=0.039), hepatitis (RR=0.57, 95% CI=0.45-0.73, P=0.000), liver cirrhosis (RR=0.56, 95% CI=0.31-1.01, P=0.053) and chronic liver disease (RR=0.49, 95% CI=0.29-0.82, P=0.007). This trend is also observed regardless of the race of the individual concerned where the Asian, American and European subgroups all demonstrated a reduced risk of liver disease. CONCLUSIONS: Green tea intake reduces the risk of liver disease. However, more long term randomized clinical trials are needed to comprehensively evaluate the health benefits of green tea.
Entities:
Keywords:
Green tea; liver disease; meta-analysis; risk
Authors: Yanli Li; Shen-Chih Chang; Binh Y Goldstein; William L Scheider; Lin Cai; Nai-Chieh Y You; Heather P Tarleton; Baoguo Ding; Jinkou Zhao; Ming Wu; Qingwu Jiang; Shunzhang Yu; Jianyu Rao; Qing-Yi Lu; Zuo-Feng Zhang; Lina Mu Journal: Cancer Epidemiol Date: 2011-02-10 Impact factor: 2.984
Authors: Christina Bamia; Pagona Lagiou; Mazda Jenab; Antonia Trichopoulou; Veronika Fedirko; Krasimira Aleksandrova; Tobias Pischon; Kim Overvad; Anja Olsen; Anne Tjønneland; Marie-Christine Boutron-Ruault; Guy Fagherazzi; Antoine Racine; Tilman Kuhn; Heiner Boeing; Anna Floegel; Vasiliki Benetou; Domenico Palli; Sara Grioni; Salvatore Panico; Rosario Tumino; Paolo Vineis; H B Bueno-de-Mesquita; Vincent K Dik; Nirmala Bhoo-Pathy; Cuno S P M Uiterwaal; Elisabete Weiderpass; Eiliv Lund; J Ramón Quirós; Raul Zamora-Ros; Esther Molina-Montes; Maria-Dolores Chirlaque; Eva Ardanaz; Miren Dorronsoro; Björn Lindkvist; Peter Wallström; Lena Maria Nilsson; Malin Sund; Kay-Tee Khaw; Nick Wareham; Kathryn E Bradbury; Ruth C Travis; Pietro Ferrari; Talita Duarte-Salles; Magdalena Stepien; Marc Gunter; Neil Murphy; Elio Riboli; Dimitrios Trichopoulos Journal: Int J Cancer Date: 2014-09-24 Impact factor: 7.396
Authors: M L Arffa; M A Zapf; A N Kothari; V Chang; G N Gupta; X Ding; M M Al-Gayyar; W Syn; N M Elsherbiny; P C Kuo; Z Mi Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240